{"id":5696,"date":"2026-02-19T17:18:41","date_gmt":"2026-02-19T17:18:41","guid":{"rendered":"https:\/\/oncopeptides.com\/investors\/foretradesemission-2026\/"},"modified":"2026-03-18T15:07:15","modified_gmt":"2026-03-18T15:07:15","slug":"foretradesemission-2026","status":"publish","type":"investors","link":"https:\/\/oncopeptides.com\/sv\/investerare\/aktien\/nyemissioner\/foretradesemission-2026\/","title":{"rendered":"F\u00f6retr\u00e4desemission 2026"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"5696\" class=\"elementor elementor-5696 elementor-5531\" data-elementor-post-type=\"investors\">\n\t\t\t\t<style>\n                .elementor-element-76ecfb7{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-76ecfb7 e-flex e-con-boxed e-con e-parent\" data-id=\"76ecfb7\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<style>\n                .elementor-element-81f1eb6{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-81f1eb6 e-con-full haus-2-1 e-flex e-con e-child\" data-id=\"81f1eb6\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-51acc77 elementor-widget elementor-widget-heading\" data-id=\"51acc77\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">F\u00f6retr\u00e4desemission<br><span style=\"color: var(--color-orange)\">2026<\/span><\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e02dd42 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"e02dd42\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-1e48cb6{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-1e48cb6 e-con-full e-flex e-con e-child\" data-id=\"1e48cb6\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-0b7ca8e elementor-widget elementor-widget-text-editor\" data-id=\"0b7ca8e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h2>Utfall i Oncopeptides f\u00f6retr\u00e4desemission<\/h2>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-18ea205 elementor-widget elementor-widget-text-editor\" data-id=\"18ea205\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<strong>17 mars 2026 &#8211; Oncopeptides AB (publ) offentligg\u00f6r utfallet i den delvis garanterade f\u00f6retr\u00e4desemissionen om cirka 200 miljoner kronor (\u201cF\u00f6retr\u00e4desemissionen\u201d).<\/strong> Teckningsperioden f\u00f6r F\u00f6retr\u00e4desemissionen avslutades den 16 mars 2026. Utfallet visar att 77 082 970 stamaktier, motsvarande cirka 60 procent av de erbjudna stamaktierna, har tecknats med st\u00f6d av teckningsr\u00e4tter i F\u00f6retr\u00e4desemissionen. D\u00e4rut\u00f6ver har anm\u00e4lningar om teckning av 3 096 716 stamaktier utan st\u00f6d av teckningsr\u00e4tter, motsvarande cirka 2 procent av de erbjudna stamaktierna, inkommit. D\u00e4rf\u00f6r kommer cirka 33 procent av F\u00f6retr\u00e4desemissionen att tilldelas parter som ing\u00e5tt garanti\u00e5taganden. F\u00f6retr\u00e4desemissionen kommer att tillf\u00f6ra Bolaget cirka 190 miljoner kronor f\u00f6re avdrag f\u00f6r transaktionskostnader relaterade till F\u00f6retr\u00e4desemissionen.   \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-27119e2 elementor-widget elementor-widget-button\" data-id=\"27119e2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/oncopeptides.com\/sv\/pressmeddelanden\/utfall-i-oncopeptides-foretradesemission\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">L\u00e4s pressmeddelandet<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-ebd91ba elementor-widget elementor-widget-text-editor\" data-id=\"ebd91ba\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p><strong>Hitta Fr\u00e5gor och Svar f\u00f6r investerare, Biostock presentation, Oncopeptalks, Redeye intervju, pressmeddelanden samt dokument till f\u00f6retr\u00e4desemissionen nedan.<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-50e9ad6 elementor-widget elementor-widget-text-editor\" data-id=\"50e9ad6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h2>Emissionen i korthet<\/h2><ul><li><strong>Teckningsperiod<\/strong>: 2\u201316 mars 2026<\/li><li><strong>Teckningskurs<\/strong>: 1,55 SEK per aktie<\/li><li><strong>Villkor<\/strong>: Nuvarande aktie\u00e4gare (registrerade p\u00e5 avst\u00e4mningsdagen den 26 februari 2026) erh\u00e5ller en teckningsr\u00e4tt f\u00f6r varje befintlig stamaktie. Teckningsr\u00e4tten ger innehavaren f\u00f6retr\u00e4desr\u00e4tt att teckna nya stamaktier, d\u00e4r tv\u00e5 (2) teckningsr\u00e4tter ger innehavaren r\u00e4tt att teckna en (1) ny stamaktie. Dessutom kommer det att vara m\u00f6jligt f\u00f6r investerare att ans\u00f6ka om teckning av aktier utan teckningsr\u00e4tter.  <\/li><li><strong>Garanti<\/strong>: F\u00f6retr\u00e4desemissionen \u00e4r s\u00e4kerst\u00e4lld genom teckningsf\u00f6rbindelser fr\u00e5n bland andra st\u00f6rsta \u00e4garen HealthCap VIII LP samt garanti\u00e5taganden fr\u00e5n externa investerare, inklusive DNB Bank ASA, upp till totalt cirka 190 MSEK.<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3f75055 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"3f75055\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-de476fb{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-de476fb e-con-full e-flex e-con e-child\" data-id=\"de476fb\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-ac4c6c0 elementor-widget elementor-widget-image\" data-id=\"ac4c6c0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<webien-image class=\" has-thumb ratio-original\">\r\n\t<img fetchpriority=\"high\" decoding=\"async\" src=\"https:\/\/c1.webien.cloud\/pixel.webp\" width=\"2330\" height=\"547\" data-srcset=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2025\/08\/sofia-heigis_img_5061_foto-liza-simonsson-hero-image.jpg\" data-original=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2025\/08\/sofia-heigis_img_5061_foto-liza-simonsson-hero-image.jpg\" data-optimize=\"1\" data-useoriginal=\"0\" data-ratio=\"none\" data-sizes=\"auto\" data-focus=\"attention\" class=\"main lazyload\" title=\"sofia-heigis_img_5061_foto-liza-simonsson-hero-image\" alt=\"\" \/>\r\n\t\r\n\t<img decoding=\"async\" width=\"2330\" height=\"547\" src=\"https:\/\/wrooom.webien.io\/eyJpbWFnZVVybCI6Imh0dHBzOi8vb25jb3BlcHRpZGVzLmNvbS93cC1jb250ZW50L3VwbG9hZHMvMjAyNS8wOC9zb2ZpYS1oZWlnaXNfaW1nXzUwNjFfZm90by1saXphLXNpbW9uc3Nvbi1oZXJvLWltYWdlLmpwZyIsInB1YmxpY0tleSI6Im5vS2V5IiwiZWRpdHMiOnsicmVzaXplIjp7IndpZHRoIjoxNTAsImhlaWdodCI6MTUwLCJmaXQiOiJpbnNpZGUiLCJwb3NpdGlvbiI6ImF0dGVudGlvbiIsIndpdGhvdXRFbmxhcmdlbWVudCI6dHJ1ZX0sImJsdXIiOjEyfX0=\" class=\"thumb\" \/>\r\n\t<\/webien-image>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-bb1c66e elementor-widget elementor-widget-heading\" data-id=\"bb1c66e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Prelimin\u00e4r tidsplan f\u00f6r F\u00f6retr\u00e4desemissionen<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-dfbeb60 elementor-widget elementor-widget-text-editor\" data-id=\"dfbeb60\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Nedan tidsplan f\u00f6r F\u00f6retr\u00e4desemissionen \u00e4r prelimin\u00e4r och kan komma att justeras.<br><br><\/p><table width=\"614\"><tbody><tr><td width=\"454\">Avst\u00e4mningsdag f\u00f6r r\u00e4tten att erh\u00e5lla teckningsr\u00e4tter<\/td><td width=\"161\">26 februari 2026<\/td><\/tr><tr><td width=\"454\">Handel med teckningsr\u00e4tter<\/td><td width=\"161\">2 \u2013 11 mars 2026<\/td><\/tr><tr><td width=\"454\">Teckningsperiod<\/td><td width=\"161\">2 \u2013 16 mars 2026<\/td><\/tr><tr><td width=\"454\">Handel med BTA (Betald Tecknad Aktie)<\/td><td width=\"161\">2 \u2013 23 mars 2026<\/td><\/tr><tr><td width=\"454\">Offentligg\u00f6rande av utfallet i F\u00f6retr\u00e4desemissionen<\/td><td width=\"161\">Omkring18 mars 2026<\/td><\/tr><\/tbody><\/table>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0e56c82 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"0e56c82\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6ba2075 elementor-widget elementor-widget-spacer\" data-id=\"6ba2075\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-12400ac{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-12400ac e-con-full e-flex e-con e-child\" data-id=\"12400ac\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-5b9df2d elementor-widget elementor-widget-heading\" data-id=\"5b9df2d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Biostock: presentation och intervju med Sofia Heigis<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0480447 elementor-widget elementor-widget-image\" data-id=\"0480447\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"800\" height=\"450\" src=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/03\/oncopeptides-investor-pitch-biostock.webp\" class=\"attachment-full size-full wp-image-5695\" alt=\"\" sizes=\"(max-width: 800px) 100vw, 800px\" srcset=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/03\/oncopeptides-investor-pitch-biostock.webp 800w, https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/03\/oncopeptides-investor-pitch-biostock-300x169.webp 300w, https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/03\/oncopeptides-investor-pitch-biostock-768x432.webp 768w\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0594f13 elementor-widget elementor-widget-text-editor\" data-id=\"0594f13\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>5 mars 2026 &#8211; Sofia Heigis, vd f\u00f6r Oncopeptides, bes\u00f6kte nyligen Biostocks studio f\u00f6r att presentera f\u00f6retaget, dess ambitioner f\u00f6r Pepaxti i Europa och resten av v\u00e4rlden samt beskriva f\u00f6retagets strategiska omst\u00e4llning till ett globalt bioteknikbolag med flera indikationer, drivet av dess glioblastomprojekt. Presentationen f\u00f6ljs av en fr\u00e5gestund med Jonas S\u00f6derstr\u00f6m, managing partner p\u00e5 Biostock. <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3c51bb7 elementor-widget elementor-widget-button\" data-id=\"3c51bb7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/biostock.se\/2026\/03\/biostock-investor-pitch-oncopeptides-3\/\" target=\"_blank\" rel=\"noopener\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Se intervjun h\u00e4r<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a3356b4 elementor-widget elementor-widget-button\" data-id=\"a3356b4\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/biostock.se\/2026\/03\/omtag-i-tyskland-och-ny-indikation-oncopeptides-vd-berattar-mer\" target=\"_blank\" rel=\"noopener\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Du kan \u00e4ven se en l\u00e4ngre intervju med Sofia h\u00e4r<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-065a775 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"065a775\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-14dd639 elementor-widget elementor-widget-spacer\" data-id=\"14dd639\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-a46866e{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-a46866e e-con-full e-flex e-con e-child\" data-id=\"a46866e\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-011bd53 elementor-widget elementor-widget-heading\" data-id=\"011bd53\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Fr\u00e5gor och svar f\u00f6r investerare<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-668b67e elementor-widget elementor-widget-text-editor\" data-id=\"668b67e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h3>1. Varf\u00f6r genomf\u00f6r Oncopeptides denna f\u00f6retr\u00e4desemission just nu och vad ska pengarna anv\u00e4ndas till?<\/h3><p><strong>Svar:<\/strong> Vi genomf\u00f6r emissionen f\u00f6r att st\u00e4rka v\u00e5r finansiella st\u00e4llning och s\u00e4kerst\u00e4lla att vi har den uth\u00e5llighet som kr\u00e4vs f\u00f6r att n\u00e5 ett positivt kassafl\u00f6de under 2027. Nettolikviden kommer prim\u00e4rt att anv\u00e4ndas f\u00f6r att finansiera den fortsatta kommersialiseringen av Pepaxti i Europa. D\u00e4rut\u00f6ver kommer en del av kapitalet att anv\u00e4ndas till ett kostnadseffektivt utvecklingsarbete avseende v\u00e5r pipeline, specifikt f\u00f6r att initiera en &#8221;window-of-opportunity&#8221;-studie i m\u00e4nniska f\u00f6r att utv\u00e4rdera v\u00e5r kandidat OPD5 mot glioblastom.  <\/p><p> <\/p><h3>2. Vilka \u00e4r villkoren f\u00f6r att delta i f\u00f6retr\u00e4desemissionen och vad \u00e4r teckningskursen?<\/h3><p>Svar: Teckningskursen \u00e4r fastst\u00e4lld till 1,55 SEK per ny stamaktie. Den som p\u00e5 avst\u00e4mningsdagen den 26 februari 2026 \u00e4r registrerad som aktie\u00e4gare erh\u00e5ller en (1) teckningsr\u00e4tt f\u00f6r varje innehavd stamaktie. Det kr\u00e4vs tv\u00e5 (2) teckningsr\u00e4tter f\u00f6r att teckna en (1) ny stamaktie. Det \u00e4r \u00e4ven m\u00f6jligt att anm\u00e4la intresse f\u00f6r att teckna aktier utan st\u00f6d av teckningsr\u00e4tter.   <\/p><p> <\/p><h3>3. Hur mycket sp\u00e4ds mitt innehav ut om jag v\u00e4ljer att inte delta i emissionen?<\/h3><p><strong>Svar: <\/strong>Om f\u00f6retr\u00e4desemissionen fulltecknas kommer antalet aktier att \u00f6ka med upp till 129 283 736 stycken. F\u00f6r aktie\u00e4gare som v\u00e4ljer att inte delta alls inneb\u00e4r detta en utsp\u00e4dning av \u00e4garandelen med maximalt cirka 33,3 procent. Du har dock m\u00f6jlighet att s\u00e4lja dina teckningsr\u00e4tter \u00f6ver b\u00f6rsen (Nasdaq Stockholm) mellan den 2 och 11 mars 2026 f\u00f6r att helt eller delvis kompensera dig f\u00f6r den ekonomiska utsp\u00e4dningseffekten.  <\/p><p> <\/p><h3>4. \u00c4r emissionen s\u00e4kerst\u00e4lld p\u00e5 f\u00f6rhand via tecknings\u00e5taganden eller garantier?<\/h3><p><strong>Svar: <\/strong>Ja, till allra st\u00f6rsta del. Bolagets st\u00f6rsta aktie\u00e4gare, HealthCap VIII LP, har \u00e5tagit sig att teckna aktier f\u00f6r 20 MSEK (motsvarande n\u00e4stan 10 procent av emissionen). Dessutom har ledning och vissa styrelseledam\u00f6ter \u00e5tagit sig att teckna f\u00f6r cirka 0,7 MSEK. D\u00e4rut\u00f6ver har vi s\u00e4krat garanti\u00e5taganden (b\u00e5de botten- och toppgarantier) fr\u00e5n ett antal investerare p\u00e5 totalt 170 MSEK. Tillsammans t\u00e4cker tecknings- och garanti\u00e5tagandena cirka 190 MSEK av den totala emissionsvolymen p\u00e5 upp till 200 MSEK.    <\/p><h3>5. Vilka \u00e4r de viktigaste datumen jag som aktie\u00e4gare m\u00e5ste ha koll p\u00e5?<\/h3><p><strong>Answer:<\/strong><\/p><ul><li><strong>26 februari 2026: <\/strong>Avst\u00e4mningsdag (du m\u00e5ste vara registrerad aktie\u00e4gare f\u00f6r att erh\u00e5lla teckningsr\u00e4tter).<\/li><li><strong>2\u201311 mars 2026: <\/strong>Handel med teckningsr\u00e4tter p\u00e5g\u00e5r p\u00e5 Nasdaq Stockholm. Vill du s\u00e4lja r\u00e4tterna m\u00e5ste det g\u00f6ras senast den 11 mars, annars f\u00f6rfaller de v\u00e4rdel\u00f6sa. <\/li><li><strong>2\u201316 mars 2026: <\/strong>Teckningsperioden p\u00e5g\u00e5r. Detta \u00e4r f\u00f6nstret f\u00f6r att teckna och betala f\u00f6r nya aktier. <\/li><li><strong>Omkring 18 mars 2026:<\/strong> Utfallet av emissionen offentligg\u00f6rs.<\/li><\/ul><p> <\/p><h3>6. Om ni n\u00e5r i m\u00e5l med ett partneravtal i Japan, hur p\u00e5verkar det behovet av denna nyemission?<\/h3><p><strong>Svar: <\/strong>Nyemissionen genomf\u00f6rs f\u00f6r att s\u00e4kerst\u00e4lla v\u00e5r grundplan: att n\u00e5 ett positivt kassafl\u00f6de under 2027 f\u00f6r egen maskin och ta v\u00e5r europeiska aff\u00e4r hela v\u00e4gen i m\u00e5l. Vi befinner oss i f\u00f6rhandlingar om licensiering av Pepaxti i Japan, och om vi framg\u00e5ngsrikt i landar detta och erh\u00e5ller licensbetalningar, avser vi att anv\u00e4nda de tillkommande medlen f\u00f6r att accelerera utvecklingen av v\u00e5r pipeline (framf\u00f6r allt OPD5) mot indikationer som glioblastom och hematologiska sjukdomar, d\u00e4r de potentiella marknadsv\u00e4rdena \u00e4r mycket stora. <\/p><p> <\/p><h3>7. Ni n\u00e4mner att en del av kapitalet g\u00e5r till FoU (R&amp;D) f\u00f6r glioblastom. Hur stora risker och kostnader tar ni p\u00e5 er i den satsningen? <\/h3><p><strong>Svar: <\/strong>V\u00e5r approach \u00e4r designad f\u00f6r att vara mycket kapital- och kostnadseffektiv. Den planerade &#8221;window-of-opportunity&#8221;-studien i m\u00e4nniska syftar till att snabbt och effektivt generera bevis f\u00f6r vidare klinisk utveckling av v\u00e5r PDC-plattform i glioblastom. F\u00f6r att h\u00e5lla kostnaderna nere har vi gjort en strategisk \u00f6versyn och kommer fram\u00f6ver i mycket st\u00f6rre utstr\u00e4ckning basera v\u00e5r forskning p\u00e5 externa och akademiska samarbeten ist\u00e4llet f\u00f6r tunga interna fasta kostnader.  <\/p><p> <\/p><h3>8. Var v\u00e4nder jag mig f\u00f6r mer information?<\/h3><p><strong>Svar: <\/strong>F\u00f6r fr\u00e5gor som r\u00f6r deltagande och sj\u00e4lva genomf\u00f6randet av nyemissionen v\u00e4nder du dig till din bank. Oncopeptides har inga m\u00f6jligheter att guida d\u00e5 vi inte har insikt i hur specifika banker hanterar emissionen, vilket kan skilja sig \u00e5t. F\u00f6r fr\u00e5gor kring motiv emissionen och bolagets ambitioner fram\u00e5t, kontakta <a href=\"mailto:ir@oncopeptides.com\">ir@oncopeptides.com<\/a>.  <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f236eed dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"f236eed\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-661ed67{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-661ed67 e-con-full e-flex e-con e-child\" data-id=\"661ed67\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-7bb2a24 elementor-widget elementor-widget-text-editor\" data-id=\"7bb2a24\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>DENNA INFORMATION F\u00c5R INTE OFFENTLIGG\u00d6RAS, PUBLICERAS ELLER DISTRIBUERAS, DIREKT ELLER INDIREKT, I ELLER TILL AUSTRALIEN, HONGKONG, ISRAEL, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, USA ELLER N\u00c5GON ANNAN JURISDIKTION D\u00c4R S\u00c5DAN \u00c5TG\u00c4RD HELT ELLER DELVIS \u00c4R F\u00d6REM\u00c5L F\u00d6R LEGALA RESTRIKTIONER. DENNA INFORMATION UTG\u00d6R INTE ETT ERBJUDANDE ATT F\u00d6RV\u00c4RVA V\u00c4RDEPAPPER I ONCOPEPTIDES AB (PUBL). <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-38a6be3 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"38a6be3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-b45f9ea{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-b45f9ea e-con-full e-flex e-con e-child\" data-id=\"b45f9ea\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-e49f06f elementor-widget elementor-widget-spacer\" data-id=\"e49f06f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4b9e662 elementor-widget elementor-widget-text-editor\" data-id=\"4b9e662\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Pressmeddelande<\/p><h2>Oncopeptides erh\u00e5ller fast-track-status f\u00f6r Window-of-Opportunity-studie i glioblastom<\/h2><p>9 mars 2026<\/p><p>Oncopeptides AB (publ) (\u201dOncopeptides\u201d eller \u201dBolaget\u201d) (Nasdaq Stockholm: ONCO) meddelar idag att bolaget har n\u00e5tt regulatorisk enighet med b\u00e5de det svenska L\u00e4kemedelsverket och det norska Direktoratet for medisinske produkter (DMP) avseende utformningen av den planerade \u201dWindow-of-Opportunity\u201d-studien (WoO). Studien utv\u00e4rderar ett peptid-l\u00e4kemedelskonjugat (PDC) i glioblastom och kommer att genomf\u00f6ras i Norge, d\u00e4r DMP har beviljat s\u00e5 kallad fast-track-status. <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-92e3b3f elementor-widget elementor-widget-button\" data-id=\"92e3b3f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/oncopeptides.com\/sv\/pressmeddelanden\/oncopeptides-erhaller-fast-track-status-for-window-of-opportunity-studie-i-glioblastom\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">L\u00e4s pressmeddelandet samt fr\u00e5gor och svar f\u00f6r investerare<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-fd9ee47 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"fd9ee47\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-669ed7f{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-669ed7f e-con-full e-flex e-con e-child\" data-id=\"669ed7f\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-afee876 elementor-widget elementor-widget-spacer\" data-id=\"afee876\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4cf7487 elementor-widget elementor-widget-text-editor\" data-id=\"4cf7487\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Pressmeddelande<\/p><h2>Oncopeptides offentligg\u00f6r informationsdokument avseende f\u00f6retr\u00e4desemission<\/h2><p>26 februari 2026 \u2013 Regulatoriskt pressmeddelande<\/p><p>Oncopeptides AB (publ) (\u201dOncopeptides\u201d eller \u201dBolaget\u201d) (Nasdaq Stockholm: ONCO) offentligg\u00f6r informationsdokument avseende Bolagets nyemission med f\u00f6retr\u00e4desr\u00e4tt f\u00f6r befintliga aktie\u00e4gare om cirka 200 MSEK, som beslutades av styrelsen den 19 februari 2026 med st\u00f6d av bemyndigande fr\u00e5n \u00e5rsst\u00e4mman den 22 maj 2025 (\u201dF\u00f6retr\u00e4desemissionen\u201d). Informationsdokumentet har registrerats hos Finansinspektionen och finns tillg\u00e4ngligt p\u00e5 Bolagets webbplats. <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-9bc32f6 elementor-widget elementor-widget-button\" data-id=\"9bc32f6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/oncopeptides.com\/sv\/pressmeddelanden\/oncopeptides-offentliggor-informationsdokument-avseende-foretradesemission-2\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">L\u00e4s pressmeddelandet<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-cf41c30 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"cf41c30\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-845b7c8{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-845b7c8 e-con-full e-flex e-con e-child\" data-id=\"845b7c8\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-4c797e4 elementor-widget elementor-widget-spacer\" data-id=\"4c797e4\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e12a5c6 elementor-widget elementor-widget-heading\" data-id=\"e12a5c6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Information om anm\u00e4lningssedlarna<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-fe560f3 elementor-widget elementor-widget-text-editor\" data-id=\"fe560f3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>V\u00e4nligen notera att anm\u00e4lningssedlarna nedan \u00e4r f\u00f6r direkt\u00e4gande aktie\u00e4gare. \u00c4ger du aktier via din bank, exempelvis Avanza eller Nordnet, kommer du att kunna teckna dig den v\u00e4gen. Teckningsr\u00e4tter f\u00f6r nuvarande aktie\u00e4gare kommer att distribueras den 2 mars.  <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-9415cb2{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-9415cb2 e-con-full e-flex e-con e-child\" data-id=\"9415cb2\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-26485ca elementor-widget elementor-widget-heading\" data-id=\"26485ca\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Dokument till f\u00f6retr\u00e4desemissionen<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a10f49c elementor-position-inline-end elementor-view-default elementor-widget elementor-widget-icon-box\" data-id=\"a10f49c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-box.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-icon-box-wrapper\">\n\n\t\t\t\t\t\t<div class=\"elementor-icon-box-icon\">\n\t\t\t\t<a href=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/03\/oncopeptides-bilaga-ix-informationsdokument-2026-swe.pdf\" target=\"_blank\" class=\"elementor-icon\" tabindex=\"-1\" aria-label=\"Informationsdokument - F\u00f6retr\u00e4desemission 2026\">\n\t\t\t\t<i aria-hidden=\"true\" class=\"onco onco-Download-3\"><\/i>\t\t\t\t<\/a>\n\t\t\t<\/div>\n\t\t\t\n\t\t\t\t\t\t<div class=\"elementor-icon-box-content\">\n\n\t\t\t\t\t\t\t\t\t<h3 class=\"elementor-icon-box-title\">\n\t\t\t\t\t\t<a href=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/03\/oncopeptides-bilaga-ix-informationsdokument-2026-swe.pdf\" target=\"_blank\">\n\t\t\t\t\t\t\tInformationsdokument - F\u00f6retr\u00e4desemission 2026\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h3>\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t<p class=\"elementor-icon-box-description\">\n\t\t\t\t\t\tpdf, 255 KB\t\t\t\t\t<\/p>\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-62bb6cb elementor-position-inline-end elementor-view-default elementor-widget elementor-widget-icon-box\" data-id=\"62bb6cb\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-box.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-icon-box-wrapper\">\n\n\t\t\t\t\t\t<div class=\"elementor-icon-box-icon\">\n\t\t\t\t<a href=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/03\/oncopeptides-anmalningssedel-2026-med-foretradesratt-eng.pdf\" target=\"_blank\" class=\"elementor-icon\" tabindex=\"-1\" aria-label=\"Oncopeptides anm\u00e4lningssedel - Med F\u00f6retr\u00e4desr\u00e4tt\">\n\t\t\t\t<i aria-hidden=\"true\" class=\"onco onco-Download-3\"><\/i>\t\t\t\t<\/a>\n\t\t\t<\/div>\n\t\t\t\n\t\t\t\t\t\t<div class=\"elementor-icon-box-content\">\n\n\t\t\t\t\t\t\t\t\t<h3 class=\"elementor-icon-box-title\">\n\t\t\t\t\t\t<a href=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/03\/oncopeptides-anmalningssedel-2026-med-foretradesratt-eng.pdf\" target=\"_blank\">\n\t\t\t\t\t\t\tOncopeptides anm\u00e4lningssedel - Med F\u00f6retr\u00e4desr\u00e4tt\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h3>\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t<p class=\"elementor-icon-box-description\">\n\t\t\t\t\t\tpdf, 446 KB\t\t\t\t\t<\/p>\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0b9298e elementor-position-inline-end elementor-view-default elementor-widget elementor-widget-icon-box\" data-id=\"0b9298e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-box.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-icon-box-wrapper\">\n\n\t\t\t\t\t\t<div class=\"elementor-icon-box-icon\">\n\t\t\t\t<a href=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/03\/oncopeptides-anmalningssedel-2026-utan-foretradesratt-eng.pdf\" target=\"_blank\" class=\"elementor-icon\" tabindex=\"-1\" aria-label=\"Oncopeptides anm\u00e4lningssedel - Utan F\u00f6retr\u00e4desr\u00e4tt\">\n\t\t\t\t<i aria-hidden=\"true\" class=\"onco onco-Download-3\"><\/i>\t\t\t\t<\/a>\n\t\t\t<\/div>\n\t\t\t\n\t\t\t\t\t\t<div class=\"elementor-icon-box-content\">\n\n\t\t\t\t\t\t\t\t\t<h3 class=\"elementor-icon-box-title\">\n\t\t\t\t\t\t<a href=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/03\/oncopeptides-anmalningssedel-2026-utan-foretradesratt-eng.pdf\" target=\"_blank\">\n\t\t\t\t\t\t\tOncopeptides anm\u00e4lningssedel - Utan F\u00f6retr\u00e4desr\u00e4tt\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h3>\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t<p class=\"elementor-icon-box-description\">\n\t\t\t\t\t\tpdf, 457 KB\t\t\t\t\t<\/p>\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0c689db dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"0c689db\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e71746a elementor-widget elementor-widget-spacer\" data-id=\"e71746a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-23c8c7d{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-23c8c7d e-con-full e-flex e-con e-child\" data-id=\"23c8c7d\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-55acf53 elementor-widget elementor-widget-heading\" data-id=\"55acf53\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Oncopeptalks om Q4 rapporten 2025, nyemission och nyheter i pipeline<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-48032f9 elementor-widget elementor-widget-video\" data-id=\"48032f9\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;video_type&quot;:&quot;vimeo&quot;,&quot;show_image_overlay&quot;:&quot;yes&quot;,&quot;image_overlay&quot;:{&quot;url&quot;:&quot;https:\\\/\\\/oncopeptides.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/skarmbild-2026-02-23-181048.png&quot;,&quot;id&quot;:5693,&quot;size&quot;:&quot;&quot;,&quot;alt&quot;:&quot;&quot;,&quot;source&quot;:&quot;library&quot;}}\" data-widget_type=\"video.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-wrapper elementor-open-inline\">\n\t\t\t<iframe class=\"elementor-video-iframe\" allowfullscreen allow=\"clipboard-write\" title=\"vimeo-videospelare\" src=\"https:\/\/player.vimeo.com\/video\/1167423894?color&amp;autopause=0&amp;loop=0&amp;muted=0&amp;title=0&amp;portrait=0&amp;byline=0#t=\"><\/iframe>\t\t\t\t<div class=\"elementor-custom-embed-image-overlay\" style=\"background-image: url(https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/02\/skarmbild-2026-02-23-181048.png);\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"elementor-custom-embed-play\" role=\"button\" aria-label=\"Spela videoklipp\" tabindex=\"0\">\n\t\t\t\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-play\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M424.4 214.7L72.4 6.6C43.8-10.3 0 6.1 0 47.9V464c0 37.5 40.7 60.1 72.4 41.3l352-208c31.4-18.5 31.5-64.1 0-82.6z\"><\/path><\/svg>\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-29e2ae6 elementor-widget elementor-widget-text-editor\" data-id=\"29e2ae6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>23 februari 2026 &#8211; I det senaste avsnittet av Oncopeptalks diskuterar David och Sofia den nyligen sl\u00e4ppta Q4 rapporten, den p\u00e5g\u00e5ende f\u00f6retr\u00e4desemissionen samt nyheter i v\u00e5r pipeline.  <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b0c5de2 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"b0c5de2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-790ee16 elementor-widget elementor-widget-spacer\" data-id=\"790ee16\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-9799737{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-9799737 e-con-full e-flex e-con e-child\" data-id=\"9799737\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2b335ee elementor-widget elementor-widget-heading\" data-id=\"2b335ee\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Oncopeptides vd Sofia Heigis intervjuad av Redeye om Q4 och nyemissionen<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-503e617 elementor-widget elementor-widget-image\" data-id=\"503e617\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<webien-image class=\" has-thumb ratio-original\">\r\n\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/c1.webien.cloud\/pixel.webp\" width=\"2537\" height=\"1423\" data-srcset=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/02\/skarmbild-2026-02-20-092503.png\" data-original=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/02\/skarmbild-2026-02-20-092503.png\" data-optimize=\"1\" data-useoriginal=\"0\" data-ratio=\"none\" data-sizes=\"auto\" data-focus=\"attention\" class=\"main lazyload\" title=\"Sofia-Heigis-CEO-Redeye-Feb2026\" alt=\"\" \/>\r\n\t\r\n\t<img loading=\"lazy\" decoding=\"async\" width=\"2537\" height=\"1423\" src=\"https:\/\/wrooom.webien.io\/eyJpbWFnZVVybCI6Imh0dHBzOi8vb25jb3BlcHRpZGVzLmNvbS93cC1jb250ZW50L3VwbG9hZHMvMjAyNi8wMi9za2FybWJpbGQtMjAyNi0wMi0yMC0wOTI1MDMucG5nIiwicHVibGljS2V5Ijoibm9LZXkiLCJlZGl0cyI6eyJyZXNpemUiOnsid2lkdGgiOjE1MCwiaGVpZ2h0IjoxNTAsImZpdCI6Imluc2lkZSIsInBvc2l0aW9uIjoiYXR0ZW50aW9uIiwid2l0aG91dEVubGFyZ2VtZW50Ijp0cnVlfSwiYmx1ciI6M319\" class=\"thumb\" \/>\r\n\t<\/webien-image>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-087403b elementor-widget elementor-widget-text-editor\" data-id=\"087403b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>19 februari 2026 &#8211; Redeyes analytiker Richard Remanius intervjuade nyligen vd Sofia Heigis om Q4 och den kommande nyemissionen p\u00e5 ca 200 MSEK. <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c28c480 elementor-widget elementor-widget-button\" data-id=\"c28c480\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/www.redeye.se\/research\/1152801\/oncopeptides-q4-intervju-redeye-pratar-med-vd-sofia-heigis?\" target=\"_blank\" rel=\"noopener\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Se intervjun h\u00e4r<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e06cb4a dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"e06cb4a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-37e9b84 elementor-widget elementor-widget-spacer\" data-id=\"37e9b84\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-7df70db{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-7df70db e-con-full e-flex e-con e-child\" data-id=\"7df70db\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-b5edb62 elementor-widget elementor-widget-text-editor\" data-id=\"b5edb62\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\tPressmeddelande\n<h2>Oncopeptides genomf\u00f6r en f\u00f6retr\u00e4desemission om cirka 200 MSEK<\/h2>\n19 februari 2026 \u2013 Regulatoriskt pressmeddelande\n\nOncopeptides AB (publ) meddelar att styrelsen har beslutat att genomf\u00f6ra en nyemission om cirka 200 MSEK med f\u00f6retr\u00e4desr\u00e4tt f\u00f6r Bolagets befintliga aktie\u00e4gare med st\u00f6d av bemyndigandet som beviljades av \u00e5rsst\u00e4mman den 22 maj 2025. F\u00f6retr\u00e4desemissionen genomf\u00f6rs f\u00f6r att st\u00e4rka Bolagets finansiella st\u00e4llning, ge ytterligare utrymme f\u00f6r den p\u00e5g\u00e5ende kommersialiseringen av Pepaxti i Europa samt ta Bolagets prekliniska projekt avseende indikationen glioblastom fram till klinisk utvecklingsfas, vilket innefattar genomf\u00f6randet av en inledande s\u00e5 kallad \u201dwindow-of-opportunity\u201d-studie i m\u00e4nniska \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d57cbb1 elementor-widget elementor-widget-button\" data-id=\"d57cbb1\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/oncopeptides.com\/sv\/pressmeddelanden\/oncopeptides-genomfor-en-foretradesemission-om-cirka-200-msek\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">L\u00e4s pressmeddelandet<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6993ba7 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"6993ba7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b732cc3 elementor-widget elementor-widget-spacer\" data-id=\"b732cc3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"featured_media":0,"parent":5698,"menu_order":0,"template":"","meta":{"_acf_changed":false},"protected-content":[341],"class_list":["post-5696","investors","type-investors","status-publish","hentry","protected-content-show-disclaimer"],"acf":[],"_links":{"self":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors\/5696","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors"}],"about":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/types\/investors"}],"version-history":[{"count":5,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors\/5696\/revisions"}],"predecessor-version":[{"id":6804,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors\/5696\/revisions\/6804"}],"up":[{"embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors\/5698"}],"wp:attachment":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/media?parent=5696"}],"wp:term":[{"taxonomy":"protected-content","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/protected-content?post=5696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}